Exon skipping of midkine pre-mRNA is enhanced by intronic polymorphism in a colon cancer cell line

Cancer Letters

Volumn 207, Issue 1, 2004, Pages 89-93

  Nobata, Shigenori ^a,b   Mogi, Hidetaka ^a   Shinozawa, Takao ^a  

^a GUNMA UNIVERSITY   (Japan)

^b Gunma Analysis Center Co Ltd   (Japan)

Author keywords

Bp, base pair; Exon skipping; FBS, fetal bovine serum; Midkine; MK, midkine; Polymorphism; RT PCR, reverse transcription polymerase chain reaction; SNPs, single nucleotide polymorphisms; Splicing; Truncated midkine

Indexed keywords

GUANINE NUCLEOTIDE; MESSENGER RNA; MIDKINE; PYRIMIDINE NUCLEOTIDE;

ALTERNATIVE RNA SPLICING; AMINO ACID SUBSTITUTION; ARTICLE; CANCER CELL CULTURE; CELL HETEROGENEITY; COLON CARCINOMA; CONTROLLED STUDY; DNA POLYMORPHISM; ENHANCER REGION; EXON; GENE EXPRESSION REGULATION; GENE LOCATION; GENETIC CORRELATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INTRON; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

BASE SEQUENCE; CARRIER PROTEINS; CELL LINE, TUMOR; CLONING, MOLECULAR; COLONIC NEOPLASMS; CYTOKINES; EXONS; HUMANS; INTRONS; MODELS, GENETIC; MOLECULAR SEQUENCE DATA; POLYMORPHISM, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEQUENCE ANALYSIS, DNA; TRANSFECTION;

BOVINAE;

EID: 1842420481     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2003.10.012     Document Type: Article

References (31)

1. Kadomatsu K., Tomomura M., Muramatsu T. cDNA cloning and sequencing of a new gene intensely expressed in early differentiation stages of embryonal carcinoma cells and in mid-gestation period of mouse embryogenesis. Biochem. Biophys. Res. Commun. 151:1988;1312-1318.
2. Tomomura M., Kadomatsu K., Matsubara S., Muramatsu T. A retinoic acid-responsive gene, MK, found in the teratocarcinoma system, heterogeneity of the transcript and the nature of the translation product. J. Biol. Chem. 265:1990;10765-10770.
3. Muramatsu T. Midkine (MK), the product of a retinoic acid responsive gene, and pleiotrophin constitute a new protein family regulating growth and differentiation. Int. J. Dev. Biol. 37:1993;183-188.
4. Asai T., Watanabe K., Ichihara-Tanaka K., Kaneda N., Kojima S., Iguchi A., Inagaki F., Muramatsu T. Identification of heparin-binding sites in midkine and their role in neurite-promotion. Biochem. Biophys. Res. Commun. 236:1997;66-70.
5. Kaneda N., Talukder A.H., Nishiyama H., Koizumi S., Muramatsu T. Midkine, a heparin-binding growth/differentiation factor, exhibits nerve cell adhesion and guidance activity for neurite outgrowth in vitro. J. Biochem. 119:1996;1150-1156.
6. Akhter S., Ichihara-Tanaka K., Kojima S., Muramatsu H., Inui T., Kimura T., et al. Clusters of basic amino acids in midkine: roles in neurite-promoting activity and plasminogen activator-enhancing activity. J. Biochem. 123:1998;1127-1136.
7. Kojima S., Muramatsu H., Amanuma H., Muramatsu T. Midkine enhances fibrinolytic activity of bovine endothelial cells. J. Biol. Chem. 270:1995;9590-9596.
8. Choudhuri R., Zhang H.T., Donnini S., Ziche M., Bicknell R. An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis. Cancer Res. 57:1997;1814-1819.
9. Tsutsui J., Kadomatsu K., Matsubara S., Nakagawara A., Hamanoue M., Takao S., et al. A new family of heparin-binding growth/differentiation factors: increased midkine expression in Wilms' tumor and other human carcinomas. Cancer Res. 53:1993;1281-1285.
10. Garver R. Jr., Radford D.M., Doris-Keller H., Wick M.R., Milner P.G. Midkine and pleiotrophin expression in normal and malignant breast tissue. Cancer. 74:1994;1584-1590.
11. Aridome K., Tsutsui J., Takao S., Kadomatsu K., Ozawa M., Aikou T., Muramatsu T. Increased midkine gene expression in human gastrointestinal cancers. Jpn. J. Cancer Res. 86:1995;655-661.
12. Nakanishi T., Kadomatsu K., Okamoto T., Tomoda Y., Muramatsu T. Expression of midkine and pleiotrophin in ovarian tumors. Obstet. Glynecol. 90:1997;285-290.
13. Kato S., Ishihara K., Shinozawa T., Yamaguchi H., Asano Y., Saito M., et al. Monoclonal antibody to human midkine reveals increased midkine expression in human brain tumors. J. Neuropathol. Exp. Neurol. 58:1999;430-441.
14. Kato M., Shinozawa T., Kato S., Awaya A., Terada T. Increased midkine expression in hepatocellular carcinoma. Arch. Pathol. Lab. Med. 124:2000;848-852.
15. Kato M., Shinozawa T., Kato S., Endo K., Terada T. Increased midkine expression in intrahepatic cholangiocarcinoma: immunohistochemical and in situ hybridization analyses. Liver. 20:2000;216-221.
16. Kato M., Maeta H., Kato S., Shinozawa T., Terada T. Immunohistochemical and in situ hybridization analyses of midkine expression in thyroid papillary carcinoma. Mod. Pathol. 13:2000;1060-1065.
17. Miyashiro I., Kaname T., Shin E., Wakasugi E., Monden T., Takatsuka Y., et al. Midkine expression in human breast cancers: expression of truncated form. Breast Cancer Res. Treat. 43:1997;1-6.
18. Aridome K., Takao S., Kaname T., Kadomatsu K., Natsugoe S., Kijima F., Aikou T., Muramatsu T. Truncated midkine as a marker of diagnosis and detection of nodal metastases in gastrointestinal carcinomas. Br. J. Cancer. 78:1998;472-477.
19. Miyashiro I., Kaname T., Nakayama T., Nakamori S., Yagyu T., Monden T., et al. Expression of truncated midkine in human colorectal cancers. Cancer Lett. 106:1996;287-291.
20. Paul S., Mitsumoto T., Asano Y., Kato S., Kato M., Shinozawa T. Detection of truncated midkine in Wilms' tumor by a monoclonal antibody against human recombinant truncated midkine. Cancer Lett. 163:2001;245-251.
21. Kato M., Shinozawa T., Kato S., Terada T. Immunohistochemical localization of truncated midkine in developing human bile ducts. Histol. Histopathol. 18:2003;129-134.
22. Farzaneh-Far A., Davies J.D., Braam L.A., Spronk H.M., Proudfoot D., Chan S.W., et al. A polymorphism of the human matrix γ-carboxyglutamic acid protein promoter alters binding of an activating protein-1 complex and is associated with altered transcription and serum levels. J. Biol. Chem. 276:2001;32466-32473.
23. Forsberg L., Lyrenäs L., Faire U.D., Morgenstern R. A common functional C-T substitution polymorphism in the promoter region of the human catalase gene influences transcription factor binding, reporter gene transcription and is correlated to blood catalase levels. Free Radic. Biol. Med. 30:2001;500-505.
24. Gelmann E.P., Steadman D.J., Ma J., Ahronovitz N., Voeller H.J., Swope S., et al. Occurrence of NKX3.1 C154T polymorphism in men with and without prostate cancer and studies of its effect on protein function. Cancer Res. 62:2002;2654-2659.
25. Faustino N.A., Cooper T.A. Pre-mRNA splicing and human disease. Genes Dev. 17:2003;419-437.
26. Lynch K.W., Weiss A. A CD45 polymorphism associated with multiple sclerosis disrupts an exonic splicing silencer. J. Biol. Chem. 276:2001;24341-24347.
27. Jiang Z., Cote J., Kwon J.M., Goate A.M., Wu J.Y. Aberrant splicing of tau pre-mRNA caused by intronic mutations associated with the inherited dementia frontotemporal dementia with parkinsonism linked to chromosome 17. Mol. Cell. Biol. 20:2000;4036-4048.
28. Robbins D.H., Itzkowitz S.H. The molecular and genetic basis of colon cancer. Med. Clin. N. Am. 86:2002;1467-1495.
29. Sugiyama K., Hitomi Y., Adachi H., Esumi H. Cell type specific patterns of mRNA splicing in hepatoma cells transfected with the mutated albumin minigene of Nagase analbuminemic rats. Cancer Lett. 83:1994;221-227.
30. Carstens R.P., Wagner E.J., Garcia-Blanco M.A. An intronic splicing silencer causes skipping of the IIIb exon of fibroblast growth factor receptor 2 through involvement of polypyrimidine tract binding protein. Mol. Cell. Biol. 20:2000;7388-7400.
31. Paul S., Mitsumoto T., Yamamoto I., Shinozawa T. Molecular cloning, expression and purification of truncated midkine and its growth stimulatory activity on Wilms' tumor (G401) cells. Cancer Lett. 163:2001;239-244.